1. U.S. Food and Drug Administration. Drug safety and availability: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. Available from www.fda.gov/Drugs/DrugSafety/ucm617360.htm. Accessed 5 October 2018
2. U.S. Food and Drug Administration. Steglatro (ertugliflozin), Steglujan (ertugliflozin and sitagliptin), Segluromet (ertugliflozin and metformin hydrochloride) tablets. Available from www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209803,209805,209806Orig1s000TOC.cfm. Accessed 5 October 2018
3. Pfizer. FDA approves SGLT2 inhibitor STEGLATRO™ (ertugliflozin) and fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) for adults with type 2 diabetes. Available from www.pfizer.com/news/press-release/press-release-detail/fda_approves_sglt2_inhibitor_steglatro_ertugliflozin_and_fixed_dose_combination_steglujan_ertugliflozin_and_sitagliptin_for_adults_with_type_2_diabetes. Accessed 5 October 2018
4. U.S. Food and Drug Administration. Medication guide: Steglujan (STEG-loo-jan) (ertugliflozin and sitagliptin) tablets, for oral use. Available from www.accessdata.fda.gov/drugsatfda_docs/label/2018/209805s001lbl.pdf#page=32. Accessed 5 April 2018
5. Merck, Sharp & Dohme. Steglatro (ertugliflozin) official website. Available from www.steglatro.com. Accessed 5 October 2018